BMC Molecular and Cell Biology · Nov 17, 2026

Pharmacological telomerase activation by AGS compounds attenuates senescence-associated stress in human dermal fibroblasts

By Yehuda S, Bar Gil E, Fraifeld V et al.

Background Replicative cellular senescence (CS) is characterized by a stable arrest of cell proliferation, typically triggered by progressive telomere shortening to a critical length, thereby initiating the senescence process in the absence of human telomerase reverse transcriptase (hTERT) activity. The accumulation of senescent cells has been implicated as a major driver of aging and age-related diseases. This study investigated whether pharmacological activation of telomerase using small-molecule compounds (AGS-499 and AGS-500) could modulate molecular, proliferative, and functional markers of senescence-associated stress in human dermal fibroblasts (HDFs). Methods Early-passage (P.17-P.21) and late-passage HDFs (P.41–P.66) were treated with AGS compounds. Telomerase activity was quantified in soluble and DNA-bound protein fractions using the Telomere Repeat Amplification Protocol (TRAP). hTERT mRNA expression was assessed via Quantitative real-time polymerase chain reaction (qRT-PCR). hTERT protein levels were measured by Enzyme-linked immunosorbent assay (ELISA) in DNA-bound fractions. The functional impact on senescence-associated stress was measured through Senescence-Associated β-galactosidase (SA-β-gal) staining following a 14-day treatment regimen. Proliferative capacity was assessed by carboxyfluorescein succinimidyl ester (CFSE) dilution and flow cytometry, and the motility of individual late-passage cells was assessed by time-lapse confocal microscopy. Results Treatment with AGS-499 and AGS-500 significantly elevated telomerase activity in the DNA-bound fraction, with late-passage cells exhibiting up to a 2.3-fold increase relative to untreated controls and a 3.5-fold increase relative to Dimethyl sulfoxide (DMSO) treated cells, the latter partly reflecting a vehicle-associated reduction in telomerase activity. In the soluble fraction, significant increases were observed in early-passage cultures. AGS-499 induced a significant 2-fold increase in hTERT mRNA compared to untreated cells (8.5-fold compared to DMSO-treated cells). ELISA quantification confirmed that hTERT protein levels decline significantly with passage and that AGS-499 and AGS-500 significantly increased DNA-bound hTERT protein in late-passage cells by approximately 20% relative to vehicle controls. Long-term treatment led to a ~ 25% reduction in SA-β-gal-positive cells. In CFSE-labeled P.41 cultures, AGS-500 increased the fraction of cells in the lower-CFSE intervals after 8 days to 66.15%, compared with 43.13% in DMSO-treated cells, through a broad shift of the principal fluorescence distributions rather than expansion of a minor subpopulation. In P.66 cultures, AGS-499 increased the mean cumulative migration distance of individual cells from 32.18 ± 2.79 to 42.18 ± 1.92 (p = 0.006), and AGS-500 produced a comparable increase 40.86 ± 3.93 μm (p = 0.039). Conclusions Targeted pharmacological activation of telomerase using AGS compounds partially attenuates several molecular, proliferative, and functional features of senescence-associated stress in human fibroblasts. These results support the view that senescence-associated stress retains a degree of pharmacological plasticity and highlight controlled telomerase activation as a potential strategy for attenuating age-associated cellular dysfunction, pending confirmation of the underlying telomere-dependent and telomere-independent mechanisms. Clinical trial number Not applicable.

doi.org/10.1186/s12860-026-00611-wInterventions

AgingResearch.News